Tanzania - English - Tanzania Medicinces & Medical Devices Authority

piramal pharma limited, india - isoflurane - solution - 100

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

piramal critical care incorporated, united states of america - sevoflurane - inhalation gas - 100

Zimbabwe - English - Medicines Control Authority

piramal healthcare limited - polygeline - solution; infusion - 35g/l

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

1 device (345028) -

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

piramal critical care b.v, netherlands - sufentanil - solution for injection - 50 µ/ml

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

piramal pharma limited - isoflurano - isoflurano....1.00 ml (100% v/v)

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

piramal pharma limited, india - polygeline - solution - 3.5

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

piramal critical care incorporated, united states of america - sevoflurane - liquid - 100%

United States - English - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduces serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: - the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). - the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. - the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. patients who have developed a severe reaction to allopurinol should not be restarted on the drug.

United States - English - NLM (National Library of Medicine)

slate run pharmaceuticals, llc - lurasidone hydrochloride (unii: o0p4i5851i) (lurasidone - unii:22ic88528t) - lurasidone hydrochloride tablets are indicated for: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lurasidone hydrochloride during pregnancy. for more information, contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-andresearch-programs/pregnancyregistry/ . risk summary neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery [see clinical considerations] . there are no studies of lurasidone hydrochloride use in pregnant women. the limited available data are not sufficient to inform a drug-associated risk of birth defects or miscarriage. in animal reproduction studies, no teratogenic effects were seen in pregnant rats and rabbits given lurasidone during the period of organogenesis at doses approximately 1.5- and 6-times, the maximum recommended human dose (mr